Despite the NIH budget more than tripling since 1998, the U.S. has not seen a proportional rise in breakthroughs, a phenomenon known as Eroom's Law. The core issue isn't the amount of money, but a lack of innovation in how science is funded and conducted, with incentives that discourage risk.

The Trump administration's actions have eroded the long-standing trust that the federal government will provide stable, long-term research funding. This breakdown of the 'social contract' discourages scientists from pursuing ambitious, multi-decade longitudinal studies, which are crucial for major breakthroughs but are now perceived as too risky.

Disruptions and terminations of NIH grants extend far beyond individual lab experiments into the training pipeline. Medical schools across the nation responded to federal funding instability by reducing admissions offers and enrolling fewer incoming doctoral students in biomedical research programs.

The market is currently ignoring the long-term impact of deep cuts to research funding at agencies like the NIH. While effects aren't immediate, this erosion of foundational academic science—the "proving ground" for new discoveries—poses a significant downstream risk to the entire biotech and pharma innovation pipeline.

Scientists exist in a state of economic precarity, unable to risk their careers by pursuing heterodox ideas. Without the security and prosperity afforded to other fields, they are forced to conform to established narratives to gain tenure, funding, and basic financial stability, stifling breakthrough innovation.

The public and politicians expect scientific funding to yield guaranteed results. This forces a focus on safe, incremental research. To achieve major breakthroughs for issues like climate change, society must understand that failure is a vital part of the scientific process and be willing to fund high-risk, high-reward 'gamble' projects.

To combat scientific stagnation, the government is launching 'meta-science' units to experiment with funding. One trial, 'golden tickets,' allows individual peer reviewers to unilaterally fund bold, high-risk ideas, mirroring how VCs back outlier founders.

Government funders like the NIH are inherently risk-averse. The ideal model is for philanthropists to provide initial capital for high-risk, transformative studies. Once a concept is proven and "de-risked," government bodies can then fund the larger-scale, long-term research.

While commercial conflicts of interest are heavily scrutinized, the pressure on academics to produce positive results to secure their next large institutional grant is often overlooked. This intense pressure to publish favorably creates a significant, less-acknowledged form of research bias.